Female Androgenetic Alopecia: A Separate Entity

Norwood, O’Tar T.; Lehr, Blaine

doi:10.1046/j.1524-4725.2000.99310.x

Cited by 55 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[97][98][99] It has been widely accepted that female AGA represents the female counterpart to male AGA, and they share similar changes in histology (hair follicle miniaturization) and biochemistry (increased DHT levels in the affected scalp). However, there are some evidence indicating that they are different entities and challenging the role of androgens; 100 (1) a young woman with hypopituitarism presented with typical clinical and histological features of female AGA in the absence of detectable levels of circulating androgens; 101 (2) modest efficacy of anti-androgen therapy for female AGA in comparison to the male counterpart; (3) AGA can occur in children before puberty. 102 A recent genome wide study even casted doubt on the omnipotent role of androgen in male AGA.…”

mentioning

confidence: 99%

Hormones and the pilosebaceous unit

Chen

Zouboulis

2009

Dermato-Endocrinology

View full text Add to dashboard Cite

Hormones can exert their actions through endocrine, paracrine, juxtacrine, autocrine and intracrine pathways. The skin, especially the pilosebaceous unit, can be regarded as an endocrine organ meanwhile a target of hormones, because it synthesizes miscellaneous hormones and expresses diverse hormone receptors. Over the past decade, steroid hormones, phospholipid hormones, retinoids and nuclear receptor ligands as well as the so-called stress hormones have been demonstrated to play pivotal roles in controlling the development of pilosebaceous units, lipogenesis of sebaceous glands and hair cycling. Among them, androgen is most extensively studied and of highest clinical significance. Androgen-mediated dermatoses such as acne, androgenetic alopecia and seborrhea are among the most common skin disorders, with most patients exhibiting normal circulating androgen levels. The "cutaneous hyperandrogenism" is caused by in stiu overexpression of the androgenic enzymes and hyperresponsiveness of androgen receptors. Regulation of cutaneous steroidogenesis is analogous to that in gonads and adrenals. More work is needed to explain the regional difference within and between the androgn-mediated dermatoses. The pilosebaceous unit can act as an ideal model for studies in dermato-endocrinology.

show abstract

mentioning

confidence: 99%

Hormones and the pilosebaceous unit

Chen

Zouboulis

2009

Dermato-Endocrinology

View full text Add to dashboard Cite

show abstract

“…The condition can also affect females; however, this is less well characterised and it remains controversial as to whether the two conditions are the same (Ref. 2). Certainly, the pattern of hair loss is different in women and the prevalence is lower than that in men (Ref.…”

mentioning

confidence: 99%

Androgenetic alopecia: pathogenesis and potential for therapy

Ellis

Sinclair

Harrap

2002

Expert Rev. Mol. Med.

219

170

View full text Add to dashboard Cite

Androgenetic alopecia occurs in men and women, and is characterised by the loss of hair from the scalp in a defined pattern. Determining factors appear to be genetic predisposition coupled with the presence of sufficient circulating androgens. The prevalence of this condition is high (up to 50% of white males are affected by 50 years of age) and, although there are no serious direct health consequences, the loss of scalp hair can be distressing. Knowledge of the pathogenesis of androgenetic alopecia has increased markedly in recent years. Pre-programmed follicles on the scalp undergo a transformation from long growth (anagen) and short rest (telogen) cycles, to long rest and short growth cycles. This process is coupled with progressive miniaturisation of the follicle. These changes are androgen dependent, and require the inheritance of several genes. To date, only one of these genes, which encodes the androgen receptor (AR ), has been identified. Of the many treatments available for androgenetic alopecia, only two (finasteride and minoxidil) have been scientifically shown to be useful in the treatment of hair loss. However, these therapies are variable in their effectiveness. Discovery of the involvement of the AR gene, and the identification of other genes contributing to the condition, might lead to the development of new and more effective therapies that target the condition at a more fundamental level.https://www.cambridge.org/core/terms. https://doi

show abstract

“…Also increasing hours of cap wearing among males with androgenic alopecia showed decrease in interest to seek medical treatment (p=0.001) which implies that wearing a cap for a longer period of time helps to ward off the social stigma and the psychological effects of alopecia in them. This study serves as a baseline to help physicians understand the effects on quality of life in patients with androgenic alopecia as well as in prescribing cap wearing for them on a long term daily basis [25][26][27][28][29][30][31][32][33][34].…”

Section: Resultsmentioning

confidence: 99%